iGN Biotech Private Limited
© 2026. All rights reserved.
iGN Biotech is building India's first clinical islet transplantation programme - a proven, minimally invasive cell therapy that can free Type 1 (Allo transplantation) and Type 3C (Auto transplantation) patients from lifelong insulin dependence.
Backed & Appreciated By Recognised Institutions Of India
Modern lifestyles are affecting the health of many, and in India, diabetes is a growing concern - not just for its effects, but because sustainable, scientific solutions still aren't within everyone's reach yet.
India is the world's diabetes capital. Millions suffer from severe insulin-dependent forms — yet advanced treatments like islet transplantation don't exist in India.
For Type 1 (brittle) and Type 3C diabetes patients, the reality is lifelong insulin injections, constant glucose monitoring, and the risk of fatal hypoglycaemic episodes. Current treatments manage — they never cure.
0 Islet Transplant Centres
In India. In All Of Asia.
Islet cell transplantation extracts insulin-producing beta cells from a donor pancreas and transplants them into the patient — no major surgery, and the potential for complete insulin independence. Only ~94 centres worldwide have ever performed this procedure.
💡 What are Islets?
The Islets of Langerhans are tiny clusters of cells in the pancreas that produce insulin. In Type 1 diabetes, the immune system destroys them. By isolating healthy islets from a donor and infusing them into the patient's liver, transplanted cells take over insulin production — potentially eliminating daily injections.
4,365+
Islet allotransplants worldwide (2000–2020)
Berney et al, Transplant International (2022)
60–80%
Initial insulin independence (Year 1)
CITR Annual Report; Edmonton Protocol Review
249+
Human Islet Isolations
2
Granted Patents
80.6%
Viability Rate
2x
Higher Yield
Islet transplant centres in India. iGN Biotech is building the first.
2,608
1,475
135
119
28
Islet transplant centres in India or anywhere in Asia. iGN Biotech is building the first.
0
Centres In India
39
Centres In Europe
3
Centres In Germany
34
Centres In North America
India leads the world in diabetic population growth. The gap between need and treatment is wider here than anywhere else - and growing every year.
Market Opportunity
#1
India Ranks First in South East Asia Diabetic Population
IDF Diabetes Atlas, 11th Ed (2025)
₹200Cr+
Optimal Annual Revenue Potential for Tamil Nadu Alone
iGN Internal Market Assessment
105%
Projected Increase in Children with Type 1 Diabetes by 2045
IDF Diabetes Atlas, 10th Ed (2021)
150%
Increase in India's Diabetic Population (26M → 65M)
WHO / IDF Historical Data (1990–2016)
iGN Biotech Is Building India's First Dedicated Islet Isolation Lab, Bringing Advanced Transplantation Science Closer To Patients And Healthcare Institutions. Our State-Of-The-Art Infrastructure, Clinical Expertise, And Globally Aligned Protocols Are Designed To Support Safer, Minimally Invasive Cell Therapy Solutions For Diabetes Management.
Explore MoreFour Stages - Rigorously Controlled, Minimally Invasive, Built On 25 Years Of Global Science.
Donor Pancreas Procurement
Cadaveric pancreas collected via India's TRANSTAN/NOTTO network. Assessed on donor age, BMI, and cold ischaemia time.
Automated Islet Isolation
Islets are isolated using the Patented method and standard Ricordi method procedures.
Purification & QC
Density gradient purification, DTZ staining, GLP-grade viability and sterility testing.
Transplantation
Islets infused into portal vein via catheter under image guidance - a day-care procedure.
Vision
Make islet transplantation an accessible, affordable standard of care across Asia - transforming diabetes from a lifelong sentence into a treatable condition.
Mission
Build India's first GMP-certified islet isolation facility, develop clinical programmes with government hospitals, and create a model replicable across South & Southeast Asia.
Partnering with pioneers in islet transplantation, including leading scientists and clinicians from Oxford, Geneva, the University of Kentucky, and Cleveland Clinic.
Dr. Nithya Kalyani
Founder & Chief Scientific Officer
Chief Scientist at Rajiv Gandhi Government General Hospital leading the Islet Transplant Program for underserved patients. Former Chief Scientist at Apollo Hospitals with 20+ years in cellular therapies, regenerative medicine, and international collaborations with Oxford and Geneva.
Prem Anand
Chief Executive Officer
Drives iGN's commercialisation roadmap, regulatory navigation, and stakeholder partnerships. Building the bridge between lab breakthroughs and clinical reality.
Dr. Balamurugan Appakalai
Director & Chief Technical Officer
International pioneer in islet cell isolation with 25+ years' experience and 1,500+ human islet isolations. Former faculty at University of Louisville and Cincinnati Children's Hospital.
iGN is at an inflection point. There's a role for you in India's first islet transplant programme.
Investor
Equity stakes for individuals, institutional funds, and CSR-driven corporates.
Explore Opportunity“I saw hundreds of viable pancreases discarded every year – organs that could have given diabetic patients a second chance at life.”
MoU with the Tamil Nadu Government (Rajiv Gandhi Government General Hospital)
Award from Dr. Handem, Former Health Minister of Tamil Nadu
With the Health Secretary and Additional Health Secretary, Government of Tamil Nadu.
Talk on Islet Isolation Program
Frequently Asked Questions
For patients, clinicians, and potential partners.
What is islet transplantation vs a pancreas transplant?
Islet transplantation is minimally invasive cell therapy. Instead of transplanting an entire pancreas, only insulin-producing islet cells are isolated and infused into the patient's liver through a catheter - typically a day-care procedure.
Who is eligible?
Primarily Type 1 diabetes patients with severe hypoglycaemic episodes unresponsive to standard insulin therapy, also for Type 3C diabetes (Chronic Pancreatitis) and those already on immunosuppression after kidney transplant.
Can patients stop insulin after the procedure?
~80% achieve insulin independence in year one. Long-term: 61% at 1 year, 32% at 5 years, median graft survival 5.9 years. Most retain partial function that dramatically reduces insulin needs. Many have attained insulin independence too.
Why doesn't India have this yet?
It requires GMP-grade labs, trained islet biologists combined with the right clinical support. iGN spent 5+ years building this - registering the process, securing government collaborations, completing 70+ isolations, and obtaining patents.
Do patients need immunosuppression?
Yes, like any donor-tissue transplant. Modern steroid-free protocols are much better tolerated. Research into islet encapsulation may eventually eliminate this requirement.
iGN is at an inflection point. There's a role for you in India's first islet transplant programme.
Infrastructure, clinical operations, or regulatory strategy.
ICMR Supported
|DBT India Alliance
|Patent Approved
|Oxford Collaboration